Abstract: The effective constituent of human therapeutic morphine vaccine is morphine-6-succinate-BSA which would be produced by mixed anhydride method. By injection of 3 doses of vaccine at the interval of 0-30-60 days, humoral immunity would be caused in addicts. In this study 347 morphine addicted volunteers were vaccinated with therapeutic morphine vaccine according to WHO and national vaccination protocol. The variables were doses of vaccine, concentration of anti- morphine antibody, total protein and gamaglobuline. Volunteers were bled and then injected at the interval of 0-30-60 days. All subjects were bled at day 90 and after 1 year, 10% of them were bled randomly. Total protein and gamaglobuline were determined by serum electrophoresis and anti-morphine antibody level was estimated by ELISA. Considered variables were directly correlated with number of injections that were detected on 30 days after the first injection reaching their peak by three months after first injections and were not declined to the baseline by 1 year. All subjects were followed up and monitored for 1 year. The vaccine was well tolerated by addicted volunteers and had no serious drug-related adverse events. Only 1% at the first dose experienced brief post injection twitching and all subjects were immunized.